Neurocognitive Trajectories After BCMA CAR-T

Part of paid clinical trials in Charlotte, North Carolina.

Sponsor
Wake Forest University Health Sciences
Study ID
NCT07740317
Status
Not Yet Recruiting

Notify me when recruiting opens

Save your spot on the interest list for this study. We'll keep your details with this study so our team can follow up when recruiting opens.

Not yet recruiting

Add your contact details and location so we can keep your interest tied to this study.

Conditions

  • CART Therapy
  • Multiple Myeloma (MM)
  • Refractory Multiple Myeloma (RRMM)

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

  • Standardized neurocognitive testing — OTHER
    Perform standardized neurocognitive testing at baseline and serially at 1-, 6-, and 12-months post-infusion.

Study Details

The purpose of this research study is to evaluate cognitive changes over time in participants with relapsed or refractory multiple myeloma who have received chimeric antigen receptor T-cell therapy (CAR-T).

Key Dates

First listed
Jul 31, 2026
Start date
Sep 30, 2026
Status verified
Jul 2026
Primary completion
Nov 30, 2029
Completion
Nov 30, 2029

Study Design

Enrollment
50 participants (estimated)

Arms

  • Arm: Patients with RRMM
    RRMM patients being treated with SOC commercial BCMA CAR-T therapy

Primary Outcome Measure

Clinically significant cognitive impairment [ Time Frame: Baseline, 1-, 6-, and 12-months post-CAR-T ]

Central Contacts

Locations (1)

FacilityCityStateZIPSite coordinators
Atrium Health Levine CancerCharlotteNorth Carolina28204
Courtney Schepel
[email protected]
980-292-0817
Cindy Varga, MD (PRINCIPAL_INVESTIGATOR)

Find similar trials in Charlotte, NC

By research site
Atrium Health Levine Cancer· Charlotte, NC

Related Studies